Heather’s Hope: All the Advances in Pancreatic Cancer In March of 2025
March 2025 has been a pivotal month for pancreatic cancer research, with groundbreaking discoveries offering new hope for patients and their families.
From innovative treatments targeting genetic mutations to advancements in early detection, the field is making strides toward better outcomes for one of the deadliest cancers. Here’s our monthly roundup of the most promising developments on this month’s Heather’s Hope.
Targeting RAS Mutations: A Game-Changer
Pan-RAS Inhibitor Daraxonrasib
A new pan-RAS inhibitor, daraxonrasib (RMC-6236), has shown remarkable promise in targeting a broader range of RAS mutations. In a phase I trial, this drug achieved an 8.5-month median progression-free survival and 14.5-month overall survival in patients with advanced pancreatic cancer.
Unlike earlier therapies that focused on specific mutations like KRAS G12C, daraxonrasib offers hope to a larger patient population by addressing multiple RAS mutations.
VIDAR-1 TCR-T Cell Therapy
Anocca’s VIDAR-1 trial received approval to test ANOC-001, a TCR-T cell therapy targeting KRAS mutations like G12V and G12D. This first-in-human trial aims to address the unmet needs of advanced pancreatic cancer patients by leveraging non-viral gene editing for precision treatment. Enrollment is set to begin in Europe this spring, marking an exciting step forward in immunotherapy.
Advances in Early Detection
AI-Powered Imaging
Stanford University introduced an AI system capable of detecting precancerous lesions like PanINs with 87% accuracy during routine CT scans. This technology could enable earlier interventions and significantly improve outcomes for high-risk individuals.
Innovative Treatment Strategies
Precision Promise Trial Insights
The Precision Promise trial showcased how adaptive Bayesian designs can accelerate drug development. Although pamrevlumab did not meet its endpoints, the trial highlighted the potential of platform studies to refine treatments more efficiently.
Metabolic Targeting with GLS-1347
GLS-1347, a glutaminase inhibitor developed at the University of Toronto, demonstrated a disease control rate of 67% in combination with chemotherapy. By targeting cancer metabolism, this approach offers a novel way to combat tumor growth.
Expanding Access to Care in Canada
Despite these breakthroughs, Canadian patients face significant barriers to accessing clinical trials and emerging therapies. With trials concentrated in major provinces like Ontario and BC, rural and underserved populations are often excluded. Decentralized trials and national screening programs are urgently needed to bridge these gaps.
Looking Ahead
These advances are transforming pancreatic cancer from an untreatable disease into one where hope is tangible. However, systemic changes are required to ensure equitable access for all patients. The Heather Cutler Foundation remains committed to advocating for these changes while celebrating every step forward.
